Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis by Simón Talero, Macarena et al.
Accepted Manuscript
Association Between Portosystemic Shunts and Increased Complications and
Mortality in Patients With Cirrhosis
Macarena Simón-Talero, Davide Roccarina, Javier Martínez, Katharina Lampichler,
Anna Baiges, Gavin Low, Elba Llop, Michael Praktiknjo, Martin H. Maurer,
Alexander Zipprich, Michela Triolo, Guillaume Vangrinsven, Rita Garcia-Martinez,
Annette Dam, Avik Majumdar, Carmen Picón, Daniel Toth, Anna Darnell, Juan
G. Abraldes, Marta Lopez, Guido Kukuk, Aleksander Krag, Rafael Bañares, Wim
Laleman, Vincenzo La Mura, Cristina Ripoll, Annalisa Berzigotti, Jonel Trebicka,
Jose Luis Calleja, Puneeta Tandon, Virginia Hernandez-Gea, Thomas Reiberger,
Agustín Albillos, Emmanuel A. Tsochatzis, Salvador Augustin, Joan Genescà,
Sergi Quiroga, Dominic Yu, Mattias Mandorfer, Juan Carlos Garcia-Pagan, Claudia
Berbel, Jose Ferrusquia, Michel Ble, Mari Angeles Garcia-Criado, Ernest Belmonte,
Michael Ney, Cristina Margini, Stefania Casu, Giuseppe Murgia, Christiane Ludwig,
Martin Rönsch, Dietrich Stoevesandt, Laura Carrion, Enrique Ramón Botella
PII: S0016-5085(18)30069-6
DOI: 10.1053/j.gastro.2018.01.028
Reference: YGAST 61637
To appear in: Gastroenterology
Accepted Date: 15 January 2018
Please cite this article as: Simón-Talero M, Roccarina D, Martínez J, Lampichler K, Baiges A, Low G,
Llop E, Praktiknjo M, Maurer MH, Zipprich A, Triolo M, Vangrinsven G, Garcia-Martinez R, Dam A,
Majumdar A, Picón C, Toth D, Darnell A, Abraldes JG, Lopez M, Kukuk G, Krag A, Bañares R, Laleman
W, La Mura V, Ripoll C, Berzigotti A, Trebicka J, Calleja JL, Tandon P, Hernandez-Gea V, Reiberger
T, Albillos A, Tsochatzis EA, Augustin S, Genescà J, for the Baveno VI-SPSS group from the Baveno
Cooperation, Baveno VI-SPSS group, Quiroga S, Yu D, Mandorfer M, Garcia-Pagan JC, Berbel C,
Ferrusquia J, Ble M, Garcia-Criado MA, Belmonte E, Ney M, Margini C, Casu S, Murgia G, Ludwig
C, Rönsch M, Stoevesandt D, Carrion L, Botella ER, Association Between Portosystemic Shunts and
Increased Complications and Mortality in Patients With Cirrhosis, Gastroenterology (2018), doi: 10.1053/
j.gastro.2018.01.028.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
42%
64%
72%
MELD 6-9
CHILD A
MELD 10-13
CHILD B
MELD ≥14   
CHILD C
%
S
P
S
S
ALL PATIENTS
MORE HE
MELD 6-9 / CHILD-PUGH A
MORE COMPLICATIONS 
AND MORTALITY
Spleen
Kidney
Portal vein
SMV
SV
SPSS
LRV
SPSSLiver cirrhosis
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
Title: Association Between Portosystemic Shunts and Increased Complications and Mortality in 
Patients With Cirrhosis 
 
Macarena Simón-Talero
1
, Davide Roccarina
2
, Javier Martínez
3,4
, Katharina Lampichler
5
, Anna 
Baiges
4,6
, Gavin Low
7
, Elba Llop
8
, Michael Praktiknjo
9
, Martin H. Maurer
10
, Alexander Zipprich
11
, 
Michela Triolo
12
, Guillaume Vangrinsven
13
, Rita Garcia-Martinez
4,14,15
, Annette Dam
16
, Avik 
Majumdar
2
, Carmen Picón
17
, Daniel Toth
5
, Anna Darnell
18
, Juan G. Abraldes
19
, Marta Lopez
8
, Guido 
Kukuk
20
, Aleksander Krag
16
, Rafael Bañares
4,14
, Wim Laleman
13
, Vincenzo La Mura
12,21
, Cristina 
Ripoll
11
, Annalisa Berzigotti
22
, Jonel Trebicka
9,23
, Jose Luis Calleja
8
, Puneeta Tandon
19
, Virginia 
Hernandez-Gea
4,6
, Thomas Reiberger
24
, Agustín Albillos
3,4
, Emmanuel A. Tsochatzis
2
, Salvador 
Augustin
1,4
, Joan Genescà
1,4
 for the Baveno VI-SPSS group from the Baveno Cooperation.  
1
Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d´Hebron, VHIR, 
Universitat Autònoma de Barcelona, Barcelona, Spain 
2
Sheila Sherlock Liver Unit and UCL Institute for Liver and Digestive Health, Royal Free Hospital 
and UCL, London, United Kingdom  
3
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, IRICYS, 
Universidad de Alcalá, Madrid, Spain 
4
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBERehd, 
Instituto de Salud Carlos III, Madrid, Spain  
5
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, 
Vienna, Austria 
6
Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, IDIBAPS, Universitat de Barcelona, 
Barcelona, Spain 
7
Department of Radiology, University of Alberta, Edmonton, Canada 
8
Liver Unit, Hospital U. Puerta de Hierro, Universidad Autónoma de Madrid, Madrid, Spain 
9
Department of Internal Medicine I, University of Bonn, Bonn, Germany 
10
Department of Radiology, Inselspital, University of Bern, Berne, Switzerland 
11
First Department of Internal Medicine, Martin Luther University Halle-Wittenberg, Halle (Saale), 
Germany 
12
Internal Medicine, IRCCS San Donato, Department of Biomedical Sciences for Health, University 
of Milan, San Donato Milanese (MI), Italy  
13
Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium  
14
Liver Unit, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, 
Spain 
15
Instituto de investigacion Sanitaria Gregorio Marañon, Madrid, Spain 
16
Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark 
17
Department of Radiology, Hospital Universitario Ramón y Cajal, IRICYS, Universidad de Alcalá, 
Spain 
18
Department of Radiology, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain 
19
Cirrhosis Care Clinic, Division of Gastroenterology (Liver Unit), CEGIIR, University of Alberta, 
Edmonton, Canada  
20
Department of Radiology, University of Bonn, Bonn, Germany 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
21
Centro di Ricerca Coordinata “A. M. e A. Migliavacca per lo Studio e la Cura delle Malattie del 
Fegato”, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, 
Italy 
22
Hepatology, Inselspital, University of Bern, Berne, Switzerland 
23
European Foundation for Study of Chronic Liver Failure, Barcelona, Spain 
24
Division of Gastroenterology and Hepatology, Vienna Hepatic Hemodynamic Lab, Medical 
University of Vienna, Vienna, Austria 
25
Department of Radiology, Hospital Universitari Vall d´Hebron, Barcelona, Spain 
26
Department of Radiology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany 
27
Department of Radiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain 
 
Baveno VI-SPSS group: Sergi Quiroga
25
, Dominic Yu
2
, Mattias Mandorfer
24
, Juan Carlos Garcia-
Pagan
4,6
, Claudia Berbel
4,6
, Jose Ferrusquia
6
, Michel Ble
6
, Mari Angeles Garcia-Criado
6
, Ernest 
Belmonte
6
, Michael Ney
19
, Cristina Margini
22
, Stefania Casu
22
, Giuseppe Murgia
22
, Christiane 
Ludwig
11
, Martin Rönsch
26
, Dietrich Stoevesandt
26
, Laura Carrion
14
, Enrique Ramón Botella
27
. 
 
Grant support: 
Joan Genescà is a recipient of a Research Intensification grant from Instituto de Salud Carlos III. 
The study was partially funded by grants PI14/00331, PI15/00066 and PI17/00310 from Instituto 
de Salud Carlos III, Spain, and co-funded by European Union (ERDF/ESF, “Investing in your 
future”). CIBERehd is supported by Instituto de Salud Carlos III, Spain. 
Jonel Trebicka is a recipient of grants from the Deutsche Forschungsgemeinschaft (SFB TRR57), 
Cellex and European Commission H2020. 
Wim Laleman was supported by the Gilead Sciences Research Scholars Program in Liver Disease. 
Rita Garcia-Martinez is a recipient of the grant JR 14/00019 from Instituto de Salud Carlos III, 
Spain. 
  
 
Abbreviations: CI, confidence interval; CSPH, clinically significant portal hypertension; CT, 
computed tomography; EGD, esophagogastroduodenal; GI, gastrointestinal; HCV, hepatitis C 
virus; HR, hazard ratio; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; HRS, 
hepatorenal syndrome; HVPG, hepatic venous pressure gradient; IMV, inferior mesenteric vein; 
INR, International Normalized Ratio; IQR, median and interquartile range; LRV, left renal vein; L-
SPSS, large spontaneous portosystemic shunts; MELD, model for end-stage liver disease; MRI, 
magnetic resonance imaging; SBP, spontaneous bacterial peritonitis; mRS, modified Rankin Scale; 
SD, standard deviation; SMV, superior mesenteric vein; SPSS, spontaneous portosystemic shunts; 
S-SPSS, small spontaneous portosystemic shunts; SV, splenic vein; TE, transient elastography; 
TIPS, transjugular intrahepatic portosystemic shunt; W-SPSS, without spontaneous portosystemic 
shunts. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
Conflict of interest: There is not any conflict of interest to declare for any author.  
 
Corresponding authors contact information:  
Joan Genescà, MD 
Liver Unit, Department of Internal Medicine 
Hospital Universitari Vall d'Hebron 
Universitat Autònoma de Barcelona 
Pg. Vall d’Hebron, 119-129 
08035 Barcelona (Spain) 
Phone number: +34932746140 
E-mail: jgenesca@vhebron.net   
 
Salvador Augustin, MD 
Liver Unit, Department of Internal Medicine 
Hospital Universitari Vall d'Hebron 
Universitat Autònoma de Barcelona 
Pg. Vall d’Hebron, 119-129 
08035 Barcelona (Spain) 
Phone number: +34932746140 
E-mail: salva.augustin@gmail.com 
 
 
Author contributions to manuscript:  
- Study concept and design: JG, MS, SA, ET, AA, TR, VH, PT, JA, JC, JT, AB, CR, AZ, VL, WL, RB, AK. 
- Acquisition of data: MS, DR, JM, KL, GL, EL, MP, MM, MT, GV, RG, AD, AM, CP, DT, AD, ML, GK. 
- Analysis and interpretation of data: JG, MS, SA, ET, AA, TR, VH, PT, JA, JC, EL, JT, AB, CR, AZ, VL, 
WL, RB, RG, AK. 
- Drafting of the manuscript: MS, SA, JG. 
- Critical revision of the manuscript for important intellectual content: TR, PT, AB, ET, AA, VH, JA, 
JC, EL, JT, CR, AZ, VL, WL, RB, RG, AK. 
 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
Abstract:  
Background & Aims: Spontaneous portosystemic shunts (SPSSs) have been associated with 
hepatic encephalopathy (HE). Little is known about their prevalence among patients with cirrhosis 
or clinical effects. We investigated the prevalence and characteristics of SPSSs in patients with 
cirrhosis and their outcomes.  
 
Methods: We performed a retrospective study of 1729 patients with cirrhosis who underwent 
abdominal computed tomography or magnetic resonance imaging analysis from 2010 through 
2015 at 14 centers in Canada and Europe. We collected data on demographic features, etiology of 
liver disease, comorbidities, complications, treatments, laboratory and clinical parameters, model 
for end-stage liver disease (MELD) score, and endoscopy findings. Abdominal images were 
reviewed by a radiologist (or a hepatologist trained by a radiologist) and searched for the 
presence of SPSS, defined as spontaneous communications between the portal venous system or 
splanchnic veins and the systemic venous system, excluding gastroesophageal varices. Patients 
were assigned to groups with large SPSSs (L-SPSSs, ≥8 mm), small SPSSs (S-SPSSs, <8 mm), or 
without SPSS (W-SPSS). The main outcomes were the incidence of complications of cirrhosis and 
mortality according to the presence of SPSS. Secondary measurements were the prevalence of 
SPSSs in patients with cirrhosis and their radiologic features. 
 
Results: L-SPSS were identified in 488 patients (28%), S-SPSS in 548 patients (32%), and no shunt 
(W-SPSS) in 693 patients (40%). The most common L-SPSS was spleno–renal (46% of L-SPSSs). The 
presence and size of SPSS increased with liver dysfunction: among patients with MELD scores of 
6–9, 14% had L-SPSSs and 28% had S-SPSSs; among patients with MELD scores of 10–13, 30% had 
L-SPSSs and 34% had S-SPSSs; among patients with MELD scores of 14 or more, 40% had L-SPSSs 
and 32% had S-SPSSs (P<.001 for multiple comparison among MELD groups). HE was reported in 
48% of patients with L-SPSSs, 34% of patients with S-SPSSs, and 20% of patients W-SPSSs (P<.001 
for multiple comparison among SPSS groups). Recurrent or persistent HE was reported in 52% of 
patients with L-SPSSs, 44% of patients with S-SPSSs, and 37% of patients W-SPSSs (P=.007 for 
multiple comparison among SPSS groups). Patients with SPSSs also had a larger number of portal 
hypertension-related complications (bleeding or ascites) than those W-SPSSs. Quality of life and 
transplant-free survival were lower in patients with SPSSs vs without. SPSSs were an independent 
factor associated with death or liver transplantation (hazard ratio, 1.26; 95% CI, 1.06–1.49) 
(P=.008) in multivariate analysis. When patients were stratified by MELD score, SPSSs were 
associated with HE independently of liver function: among patients with MELD scores of 6–9, HE 
was reported in 23% with L-SPSSs, 12% with S-SPSSs, and 5% with W-SPSSs (P<.001 for multiple 
comparison among SPSS groups); among those with MELD scores of 10–13, HE was reported in 
48% with L-SPSSs, 33% with S-SPSSs, and 23% with W-SPSS (P<.001 for multiple comparison 
among SPSS groups); among patients with MELD scores of 14 or more, HE was reported in 59% 
with L-SPSSs, 57% with S-SPSSs, and 48% with W-SPSS (P=.043 for multiple comparison among 
SPSS groups). Patients with SPSS and MELD scores of 6–9 were at higher risk for ascites (40.5% vs 
23%; P<.001) and bleeding (15% vs 9%; P=0.038) than patients W-SPSS and had lower odds of 
transplant-free survival (hazard ratio 1.71; 95% CI, 1.16-2.51) (P=.006). 
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Conclusions: In a retrospective analysis of almost 2000 patients, we found 60% to have SPSSs; 
prevalence increases with deterioration of liver function. SPSSs increase risk for HE and chronic 
course. In patients with preserved liver function, SPSSs increase risk for complications and death. 
ClincialTrials.gov no: NCT02692430. 
KEY WORDS: collateral vessels, portal hypertension, advanced chronic liver disease, portal 
pressure 
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INTRODUCTION 
Portal hypertension is the main consequence of cirrhosis and is responsible for the majority of 
severe complications, such as ascites, variceal haemorrhage and hepatic encephalopathy (HE) 
1,2
. 
These events entail a detriment in quality of life and are associated with high mortality 
3
. 
Furthermore, clinical decompensations often require hospital admissions and close follow-up, 
implying substantial costs for the health-care system 
4
. 
One of the consequences of portal hypertension is the formation of portosystemic collateral 
vessels, commonly defined as “spontaneous portosystemic shunts” (SPSS), as an attempt to 
decompress the portal venous system 
1
. However, SPSS represent an insufficient compensatory 
mechanism, not allowing for an adequate reduction of portal pressure 
5
, but decreasing hepatic 
portal-venous perfusion 
6
. Although SPSS formation has been assumed as the result of dilatation 
of preexisting vascular channels, research studies have also implied an active process of 
neoangiogenesis 
7,8
. 
SPSS can be visualized and characterized on abdominal imaging 
9
. Their presence has been 
associated with recurrent or persistent HE 
10–12
, but very few small case-control and cohort studies 
describe the prevalence of SPSS, either using ultrasound or cross-sectional imaging methods 
13–16
. 
Moreover, identification of SPSS has potential therapeutic implications; in the last years, large 
SPSS have been assessed as a therapeutic target by embolization, especially in patients with 
preserved liver function 
17–19
. However, the true prevalence of SPSS in patients with cirrhosis 
remains unclear and whether the presence and size of SPSS are predictors of complications and 
mortality has not been systematically evaluated in large cohorts.  
The aims of the present study were (i) to determine the prevalence and characteristics of SPSS in 
cirrhosis and (ii) to assess the impact of SPSS on clinical outcomes and mortality.  
PATIENTS AND METHODS 
In this multicenter international study, data from cirrhotic patients were retrospectively assessed. 
Patients were recruited from fourteen centers: five in Spain, two in Germany, one in United 
Kingdom, Austria, Canada, Switzerland, Italy, Belgium and Denmark. The protocol, conformed to 
the Declaration of Helsinki, was approved by the ethical review boards of each participating 
center. All authors had access to the study data and reviewed and approved the final manuscript. 
Study cohort and data collection 
All cirrhotic patients older than 18 years who underwent a contrast-enhanced abdominal 
computed tomography (CT) or an abdominal magnetic resonance imaging (MRI) for any reason 
between 2010 and 2015 were consecutively selected for the study. If available, CT was the 
imaging technique of choice. The diagnosis of cirrhosis was based on medical history, liver biopsy 
or unequivocal clinical data with compatible findings on imaging techniques. Exclusion criteria 
were: presence of hepatocellular carcinoma (HCC) beyond Milan criteria, previous transjugular 
intrahepatic portosystemic shunt (TIPS) or surgical shunt, any medical condition with expected 
survival of less than 6 months, presence of neurological or psychiatric disorder preventing a 
proper HE evaluation and absence of critical information in the medical history.  
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Patients were identified in each center through a search that combined reviewing the registry of 
imaging studies ordered by the Liver Unit, the registry of the Radiological Service and coded 
diagnoses that included general terms as cirrhosis or liver disease, restricted to years 2010-2015. 
All information was anonymized, coded and gathered from medical records and clinical databases 
in every center. A coded database was used for data collection that was centrally processed.  
Patients fulfilling inclusion and lacking exclusion criteria had their medical history reviewed. Date 
of inclusion was considered the date of CT/MRI and defined as baseline. Demographic 
characteristics, etiology of liver disease, comorbidities, previous complications of cirrhosis, and 
relevant treatment were recorded. Laboratory and clinical parameters were collected at baseline. 
Data from esophagogastroduodenal (EGD) endoscopy were analyzed, if available within a 12 
month period before or after the CT/MRI. Also, liver stiffness by transient elastography (TE, 
FibroScan®, Echosens, Paris, France) and hepatic venous pressure gradient (HVPG), were also 
collected when available in the subgroup of patients with good liver function if the tests had been 
performed within a 12 month period before or after the imaging. Clinically significant portal 
hypertension (CSPH) was defined as a HVPG greater than 10 mmHg. Liver function was evaluated 
at baseline with the model for end-stage liver disease (MELD) and Child-Pugh scores 
20,21
. The 
degree of disability and dependence in daily activities was assessed through the modified Rankin 
Scale (mRS) 
17,22
. Follow-up was performed by recording all decompensating events and 
complications, including overt HE, ascites, gastrointestinal (GI) bleeding due to portal 
hypertension, hepatorenal syndrome (HRS), spontaneous bacterial peritonitis (SBP), other 
infections and development of HCC from the time of inclusion (baseline) until liver transplant, 
death or last available during the study period (until one year after the inclusion period had 
finished). HE was characterized by the grade of its worst episode (according to the West-Haven 
scale 
23
) and its clinical course, defined as episodic (isolated episodes), recurrent (in case of bouts 
that occur with a time interval of 6 months or less) or persistent (if the pattern of behavioral 
alterations was permanent) 
10,11
.  
Radiological data and definitions  
Abdominal CT and MRI were reviewed by a radiologist with expertise in hepatic disease at each 
center (in 13 of the 14 centers) or by an hepatologist trained by a radiologist (in one center) and 
instructed to search for the presence of SPSS. A predefined protocol for imaging analysis was not 
used. SPSS were considered as spontaneous communications between the portal venous system 
or splanchnic veins and the systemic venous system, excluding gastroesophageal varices. SPSS 
were classified in large or small size according to its maximum diameter, with a cut-off at 8 mm. 
This cut-off was chosen since it was the smallest size of a symptomatic shunt embolized reported 
in the literature 
24
.  According to the diameter and presence of SPSS, patients were classified into 
three groups: large SPSS (L-SPSS), small SPSS (S-SPSS) or without SPSS (W-SPSS). In addition to the 
SPSS details, other radiological information was collected (presence of portal or splanchnic vein 
thrombosis, spleen size, ascites). Splenomegaly was defined as a longitudinal diameter larger than 
13 cm. The result of a Doppler-ultrasound that had been performed closest to the CT/MRI was 
also collected, recording venous portal flow direction and velocity, if available.  
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Outcomes  
The main outcomes were the incidence of complications of cirrhosis and mortality according to 
the presence of SPSS. Secondary measurements were the prevalence of SPSS in cirrhotic patients 
and the radiological characteristics of SPSS.  
Statistical analysis  
The statistical software SPSS (version 22.0; SPSS Inc., Chicago, IL) was used for all analysis. 
Categorical variables were compared using the Pearson’s X2 test, quantitative variables were 
compared among groups using the analysis of variance (ANOVA) and Student’s t test was used for 
compare unpaired data between two groups. Results are presented in percentage, as mean and 
standard deviation (SD) or as median and interquartile range (IQR). All reported p values are two-
tailed. P values ≤0.05 were considered as statistically significant. For statistical analysis of survival, 
transplant-free survival was considered. Survival curves were performed with the Kaplan–Meier 
method and the log-rank test was used to assess differences between groups. A multivariate 
analysis was performed to estimate the adjusted effect of SPSS using the forward selection 
method. Variables were included if p value was ≤0.1 at univariate analysis. Well-known 
confounding factors (age, gender, liver function) were also included in the models regardless of p 
value at univariate analysis. Liver function was assessed separately as MELD and Child-Pugh score, 
in order to avoid collinearity. Disease duration was not included to avoid overfitting and 
collinearity with age. The selected potential confounders were assessed in a Cox proportional 
hazards model. After the global analysis, the different outcomes were stratified by MELD score to 
analyze the effect of liver function. Patients were divided and classified in three MELD subgroups 
(according to tertiles, using percentiles 33 and 66 as cut-offs). Child-Pugh stages A, B and C were 
also used for the same purpose, but MELD was prioritized over Child-Pugh for being more 
objective and not including portal hypertensive parameters such as ascites and HE (both outcome 
parameters). 
RESULTS 
From a total of 2978 patients who were assessed for eligibility (Figure 1), 1729 patients were 
included in the study and 1249 patients were excluded. L-SPSS were identified in 488 patients 
(28%), S-SPSS in 548 patients (32%) and no shunt was identified in 693 patients (W-SPSS: 40%). 
Distribution of SPSS across different centers is shown in Suppl. Table 1. The median follow-up was 
21 months (IQR 30-minimum 1 day, maximum 84 months): L-SPSS 16 months (IQR 27-1 day, 79 
months), S-SPSS 18 months (IQR 25-1 day, 84 months); W-SPSS 28 months (IQR 34-1 day, 84 
months) (p<0.001).  
Baseline characteristics and previous complications  
Baseline characteristics and previous decompensating events of the study cohort are shown in 
Table 1. Alcohol was the main etiology in L-SPSS group, while HCV infection was mostly found in 
W-SPSS group. Among the two most predominant types of L-SPSS (Table 2), alcoholic cirrhosis 
was mainly associated with paraumbilical shunts (53% of patients with paraumbilical shunts had 
alcoholic cirrhosis), and less with splenorenal shunts (37%). Patients had no differences in the 
distribution of comorbidities. Statistical differences in liver function were found: patients with L-
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SPSS had higher MELD scores and belonged more often to Child-Pugh B and C classes (Suppl. 
Figure 1) than patients with S-SPSS, and both had a worse liver function compared to the W-SPSS 
group. Biochemical parameters also showed higher serum levels of bilirubin and INR and lower 
levels of albumin, hemoglobin and platelet count in L-SPSS, followed by S-SPSS and W-SPSS. 
Patients from the L-SPSS group had experienced more complications of cirrhosis and were treated 
more frequently with liver-related drugs. Data from 1590 patients submitted to an EGD 
endoscopy were available, but only those performed 12 months before or after the CT were 
analyzed (981 patients). Patients with SPSS had a higher prevalence of esophageal varices, gastric 
varices and portal-hypertensive gastropathy, but without differences in terms of variceal size. 
Radiological characteristics  
Among the 1729 patients studied, 1630 contrast-enhanced abdominal CT and 99 abdominal MRI 
were examined. The main reason for performing the imaging study was the assessment of a 
hepatic nodule found by ultrasound (29%), followed by the characterization of the underlying liver 
disease (28%). The two techniques allowed identifying L-SPSS in a similar proportion (28% with 
CT, 34% with MRI, p=0.16).  
The most common type of L-SPSS identified was splenorenal (46%), followed by paraumbilical 
(27%) (Table 2). The mean diameter was 14 mm, with a minimum of 8 mm (according to the study 
definition) and a maximum of 50 mm. More than one L-SPSS was identified in 9% of the L-SPSS 
group. More than a third of patients (37%) with L-SPSS also had detectable small collaterals, with 
paraumbilical veins being the most common type described (48%). In the S-SPSS group, the type 
most frequently described was paraumbilical (54%), followed by splenorenal shunts (18%).  
The mean portal diameter was 14.3 mm (14.5 mm (SD 3.8 mm) in L-SPSS, 15.0 mm (SD 2.8 mm) in 
S-SPSS and 13.6 mm (SD 2.7 mm) in W-SPSS, p<0.001), suggesting a higher portal pressure in the 
SPSS groups. Portal vein thrombosis was found in 10% of the total sample (partial 5%, complete 
2% and cavernous transformation 3%). The distribution of portal vein thrombosis in relation with 
SPSS was 18% in L-SPSS (partial 7%, complete 4% and cavernous transformation 7%), 10% in S-
SPSS (partial 6%, complete 2% and cavernous transformation 3%) and 5% in W-SPSS (partial 3%, 
complete 1% and cavernous transformation 1%) (p<0.001). Moreover, 6% of the total sample had 
a splanchnic thrombosis (L-SPSS 4%, S-SPSS 1% and W-SPSS 1%; p<0.001).  
Splenomegaly was observed in 67% of the total sample (L-SPSS 81%, S-SPSS 71% and W-SPSS 54%, 
p<0.001). HCC within Milan criteria was found on 16% of the imaging tests: the percentage did 
not differ significantly in the 3 groups, neither in the size of the larger nodule, nor in the number 
of nodules. 
Data from the closest Doppler-ultrasound were collected in 1082 patients. The median time 
between study inclusion and ultrasound imaging was 3.1 months (IQR 7.9). Hepatofugal flow was 
observed more frequently in patients with L-SPSS (5% of the total sample: 13% in L-SPSS group, 
3% in S-SPSS group and 2.5% in W-SPSS group; p<0.001). In the group of patients with 
hepatopetal flow, mean velocity was slightly lower in the L-SPSS group (17.3 cm/s), compared 
with S-SPSS and W-SPSS (19.0 cm/s in both), but without statistical differences. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
Follow-up: Hepatic encephalopathy 
During follow-up, patients with L-SPSS developed episodes of HE more frequently than patients 
with S-SPSS and these than W-SPSS (48%, 34% and 20% respectively; p<0.001) (Table 3). A chronic 
course (both persistent and recurrent HE) was identified more often in the L-SPSS group, followed 
by S-SPSS and W-SPSS (25% for L-SPSS, 15% for S-SPSS and 7% for W-SPSS; p<0.001). However, 
differences in severity according to West-Haven criteria were not observed. 
Follow-up: Other complications of cirrhosis  
Patients with shunts (L-SPSS and S-SPSS) experienced portal hypertension-related GI bleeding, 
ascites, SBP and HRS more commonly during follow-up than patients of the W-SPSS group (Table 
3). There was no difference in the frequency of these complications between L-SPSS and S-SPSS 
groups. Overall 6% of patients required a TIPS during follow-up; W-SPSS patients needed a TIPS in 
a significantly lower rate than both SPSS groups. The percentage of non-SBP infections and the 
development of HCC (relapse and new diagnosis) did not differ among groups. 
Decompensating events according to the type of collateral 
According to the type of L-SPSS found, there were no differences in the kind of decompensating 
event that patients presented (Suppl. Table 2). Gastric varices were more often found in patients 
with gastrorenal shunts, an association that has been previously reported 
25
. Nevertheless, no 
differences were observed in the prevalence and size of esophageal varices across the different 
types of SPSS.  
Performance status and survival  
With regards to performance status, a higher proportion of patients from W-SPSS group were 
autonomous (mRS 0-1) compared to S-SPSS and L-SPSS (88%, 80% and 75%, respectively), while 
the rate of patients with limited activities (mRS 2-3: 12%, 19% and 23%) or disability (mRS 4-5: 0%, 
1% and 2%) was larger in the L-SPSS group (p<0.001). 
Transplant-free survival was significantly higher in the W-SPSS group, compared to S-SPSS and L-
SPSS group (log-rank test p<0.001). At the end of the follow-up period, 416 patients of the 1729 
included had died (L-SPSS 38%, S-SPSS 29% and W-SPSS 32%) and 239 had been transplanted (L-
SPSS 36%, S-SPSS 34% and W-SPSS 30%). The Hazard Ratio (HR) for death/liver transplant was 
1.36 (95% confidence interval [CI], 1.13-1.64) for S-SPSS and 1.60 (95% CI, 1.33-1.93) for L-SPSS 
(Figure 2). The most common causes of death recorded were liver failure (33%), infections (22%) 
and HCC (14%), without statistical differences among groups.  
The univariate analysis of baseline characteristics between patients alive at the end of follow-up 
and patients dead/transplanted is shown in Suppl. Table 3. Variables significantly associated with 
the outcome and entered into the multivariate model were age, gender, diabetes mellitus, 
platelet count, MELD score, HCC and presence of SPSS. Suppl. Table 4 represents the results of 
the multivariate analysis for mortality/liver transplant: age, MELD score, a diagnosis of HCC and 
presence of SPSS were independent predictors of transplant-free survival. 
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Analysis by liver function  
Analysis of the data was performed stratifying patients by MELD strata (tertiles), in order to avoid 
the possible effect that the distribution of liver function could have had on the results. Patients 
were divided in three similar groups according to their MELD score, using percentiles 33 and 66 as 
the cut-off points: the first group included scores from 6 to 9; the second group, from 10 to 13 
and the third group, from 14 onwards. Although MELD score seems more suitable to stratify 
patients according to liver function for outcome analyses including HE, we also performed the 
analysis stratifying by Child-Pugh stage.  
The independent effect of etiology in the prevalence of SPSS (higher prevalence of alcoholic 
cirrhosis) was lost in the two higher MELD groups, however it was maintained in the MELD 6-9 
group. HE remained more frequent in patients with L-SPSS, independently on their liver function 
strata, as shown in Table 4. Similar results were obtained stratifying by Child-Pugh stage (Suppl. 
Table 5). Among patients with HE, a recurrent or persistent course was identified with more 
frequency in SPSS patients with worse liver function (MELD score ≥14).  
Regarding other complications, the presence of SPSS was associated with a higher risk of portal 
hypertension-related GI bleeding and a high rate of ascites in patients with preserved liver 
function (MELD score 6-9) (Table 4) or Child-Pugh A patients (data not shown). Related to this, a 
more extensive analysis of markers of portal hypertension was performed with the available 
information in the group of patients with Child-Pugh A (Supp. Table 6). As seen, SPSS patients 
presented more indicators of portal hypertension, including HVPG values and presence of CSPH, 
than W-SPSS patients. On the other hand, presence of SPSS had an effect on outcomes 
independent of presence of CSPH. Patients with SPSS and CSPH significantly developed more 
decompensating events (34 of 50 patients, 68%) than patients without SPSS and with CSPH (12 of 
27 patients, 44%) (p= 0.047, OR 2.66, CI 1.01-6.97).   
Performance status results showed a higher percentage of limitation or disability in L-SPSS 
patients, compared to S-SPSS and W-SPSS, in the subgroup of patients with good liver function 
(MELD 6-9) (Suppl. table 7). 
Transplant-free survival in the two subgroups of patients with MELD ≥10 was not significantly 
different between SPSS patients (L-SPSS+S-SPSS) and W-SPSS patients (Figure 3B-C). However, in 
the subgroup with the lowest MELD, differences were observed (log-rank test p=0.020): HR for 
death/liver transplant was 1.57 (95% CI, 1.08-2.30) in SPSS (L-SPSS+S-SPSS) with respect to W-
SPSS group (Figure 3A). Individual HR for L-SPSS and S-SPSS are shown in Suppl. Table 8. The 
multivariate analysis including factors related to death/liver transplant (age, HCC and SPSS; Suppl. 
Table 8) in this subgroup showed that the presence of HCC (HR 4.34; 95% CI, 2.88-6.54; p<0.001) 
and SPSS (HR 1.71; 95% CI, 1.16-2.51; p=0.006) were independently associated with mortality and 
liver transplantation. Similar results were obtained by analyzing the subgroup of patients with 
Child-Pugh A; as seen in  Suppl. Figure 2, transplant-free survival was better in W-SPSS patients 
(HR for death/transplant of 1.41 [95% CI, 1.04-1.91] in SPSS patients) and the multivariate analysis 
also showed that HCC (HR 4.06; 95% CI, 2.91-5.67), diabetes mellitus (HR 1.38; 95% CI, 1.01-1.88) 
and SPSS (HR 1.49; 95% CI, 1.09-2.02) were independently associated to mortality/transplant. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
DISCUSSION 
This is the first study that evaluates a large cohort of patients with cirrhosis to determine whether 
the presence of SPSS correlates with clinical events during the course of the disease. Our results 
suggest that SPSS might develop as a consequence of a progressive increase in portal pressure 
and their presence identifies cirrhotic patients at higher risk for more complications and worse 
outcomes.  
The current study shows, first of all, that SPSS are very frequent in liver cirrhosis. In the present 
series, 60% of cirrhotic patients had some type of SPSS detected by imaging. Among L-SPSS, the 
type most often identified was splenorenal, followed by paraumbilical. This is in line with the 
results of previous small studies performed using ultrasound 
26–28
. Our study allows diagnosing 
other SPSS that can be identified more easily using cross-sectional imaging, due to the improved 
sensitivity for visualising deep vessels in comparison to ultrasound. Another interesting finding is 
that alcoholic cirrhosis is more frequently associated to SPSS than other etiologies, specifically in 
patients with preserved liver function. This is an unexplained association that was already 
reported in a study from Taiwan 
29
. In our patients, cirrhosis was diagnosed before in HCV patients 
than in alcoholic patients with respect to time of inclusion in the study. It might be plausible that 
cirrhosis secondary to chronic viral hepatitis are diagnosed earlier in the course of the disease 
that cirrhosis secondary to alcoholic liver disease. In the mention report 
29
, alcoholic cirrhotic 
patients presented five times more paraumbilical collaterals detected by ultrasound than patients 
with viral cirrhosis. In accordance with that, alcoholic cirrhosis was the predominant etiology 
(53%) in patients with paraumbilical L-SPSS. 
Another aspect to highlight is that the presence of SPSS increases considerably as liver function 
deteriorates; the finding of SPSS was more probable if MELD score was above 10 than with MELD 
6-9. Similar data were obtained with Child-Pugh staging. Our interpretation of these results is that 
increasing portal pressure is the main driving force in SPSS development. These results are in line 
with a previous small study that involved HVPG measurement and evaluation of collaterals on 
ultrasound, showing that SPSS were more often observed in patients with HVPG ≥16 mmHg 
30
. 
Regarding HE, the experience with TIPS and surgical shunts has clearly shown that portosystemic 
shunting plays a key role in HE development. After TIPS placement, the incidence of overt HE 
increases to 10-50% during the first year 
31
, with similar data obtained with surgical shunts 
32
. The 
association of HE and the presence of L-SPSS has been reported in case reports, limited clinical 
series and few small-sized case-control studies 
13–15,24,33
. Riggio, et al. 
13
 showed that the 
percentage of L-SPSS was higher among patients with recurrent or persistent HE (71%) with 
respect to the control group with no HE (14%), but in a limited sample (14 patients per group). 
The present study clearly confirms the association between HE and SPSS, especially L-SPSS, across 
all different liver function subgroups. In addition HE shows a more chronic and recurrent course in 
these patients, affecting quality of life. However, we were unable to demonstrate an association 
between SPSS and the severity of HE measure by the West-Haven scale. The reason for this is 
probably explained by the study protocol design, in which only the worst episode of HE was 
recorded, without considering the total number of grade III/IV per patient. 
With regards to the relation between SPSS and other complications of cirrhosis, the available 
information up to date was scarce and contradictory; the finding of SPSS has been related to 
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portal hypertension, but with different conclusions. The case-control study performed by Riggio et 
al. 
13
 found that patients with chronic HE and L-SPSS had less ascites, esophageal varices and 
portal-hypertensive gastropathy than patients without SPSS, suggesting than L-SPSS could have a 
protective role. Nevertheless, in former studies 
14–16
, presence of SPSS was not associated with 
lower risk of bleeding or ascites as compared to controls. Berzigotti et al. 
27
 evaluated the 
relationship between SPSS detected by ultrasound and the presence of esophageal varices, 
concluding that the development of new SPSS was associated with a higher rate of varices 
formation and growth. In the present study, SPSS were associated with more portal hypertension-
related signs and complications, such as splenomegaly, gastroesophageal varices, GI bleeding, 
ascites, HRS and SBP. This association was especially relevant in cirrhotic patients with preserved 
liver function (MELD 6-9 or Child-Pugh A), who showed higher HVPG values and more CSPH, and 
exhibited significantly more portal hypertension related complications (bleeding and ascites) 
during follow-up than patients without SPSS. In addition, the presence of SPSS in patients with 
CSPH was associated to higher rate of complications compared to W-SPSS patients with CSPH. 
Thus, the finding of SPSS in patients with good liver function probably identifies a subgroup of 
patients with more advanced portal hypertension, who are more likely to develop complications 
and might have a worse prognosis. It is worth to mention that regarding the risk of complications 
related to portal hypertension, patients with L-SPSS and S-SPSS seem to behave similarly, with a 
similar incidence of complications during follow-up. 
Even more important, however, is the association between SPSS and decreased transplant-free 
survival. Although there is a clear relationship between the presence of SPSS and liver function, 
SPSS were independently associated to mortality/transplant on multivariate analysis. Moreover, it 
is precisely in the subset of patients with low MELD (6-9) or Child-Pugh A, in which this association 
with lower survival was more remarkable. Therefore in the subgroup of cirrhotic patients with 
preserved liver function, the presence of SPSS is a prognostic marker for a higher risk of 
complications and lower survival. These patients would probably benefit from a closer 
surveillance and more intensive therapy. 
Few reports have been published about the characteristics of collaterals in cirrhosis. Some of 
them have suggested an association among the type of SPSS and the predominant kind of 
complication 
25
. Anatomically, splenorenal and gastrorenal shunts have been linked more 
frequently with gastro-esophageal varices, and an increased risk of bleeding 
28
. Paraumbilical 
shunts, that drain into the external iliac vein, without feeding the esophageal venous area, have 
been associated with less variceal bleeding and more ascites 
34,35
, while their relation with HE 
remained questionable 
36
. These results were not confirmed in other series 
37
. In this large cohort, 
an association between with the type of complication and SPSS was not observed, except for a 
higher percentage of gastric varices in gastrorenal shunts, an association already reported 
25,27
. As 
explained, HE was more frequent in L-SPSS, indicating that the diameter of the shunt plays a role 
in this complication, but portal-hypertensive complications results were similar in patients with L-
SPSS and S-SPSS, suggesting that both are indicators of severe portal hypertension.  
Our results have the limitations of a retrospective study, mainly originated from data retrieval by 
reviewing medical charts. Some data, such as HVPG, TE, ultrasound or endoscopy results, were 
not available in all patients. In addition, the lack of a predefined systematic protocol for imaging 
analysis might explain differences of SPSS prevalence among centers. Finally, imaging tests were 
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only evaluated at one time point and a prospective longitudinal study should be performed to 
analyse data about radiological improvement or deterioration according to the disease course. 
There are several strengths of the study. Participants involved were all from tertiary-care 
university hospitals, with a protocolized management of cirrhotic patients. This is the largest 
cohort ever reported about SPSS with data provided from 14 hospitals, from 9 different countries, 
allowing the generalization of the results. The review of the imaging tests by expert radiologists is 
also an added value. Finally, the stratified analysis by MELD score and Child-Pugh class is an 
important element of the study eliminating the confounding factor of liver function in the 
relationship between SPSS and clinical outcomes.  
In conclusion, SPSS are frequent in patients with cirrhosis, with splenorenal collaterals found to be 
the most common type of L-SPSS. The prevalence of SPSS increases as liver function deteriorates, 
probably as a consequence of worsening portal hypertension, but without achieving an effective 
protection against its complications. Recurrent or persistent HE is more frequent in patients with 
SPSS, independently of liver function. Patients with good liver function and SPSS develop more 
portal hypertension-related complications (GI bleeding and ascites) and have a lower transplant-
free survival. In patients with preserved liver function, SPSS therefore identifies patients with a 
higher risk of worse outcomes, and should be considered an important imaging biomarker in 
cirrhosis.  
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Table 1. Demographic and clinical characteristics of the patients included in the study 
distributed according to the presence of L-SPSS, S-SPSS or W-SPSS. 
Continuous variables are presented as mean (SD) if normally distributed and median (IQR) if 
not. Significant differences among the three groups are reported as p value. Statistical 
differences (p≤0.05) between groups are indicated as * for comparison between L-SPSS versus 
S-SPSS, ¥ for S-SPSS versus W-SPSS and § for L-SPSS versus W-SPSS. 
 Total  
(n =1729)   
L-SPSS 
(n = 488) 
S-SPSS 
(n =548) 
W-SPSS 
(n = 693) 
p 
Age (yr; mean, SD): 59 (12)  58 (12)* 59 (12) 60 (12)§  0.001 
Gender (male-%): 71 66  75  71   0.116 
Hypertension (%): 33  31  35  34  0.472 
Diabetes (%): 30  33 30 27§  0.050 
Etiology: 
Alcohol (%) 
HCV (%) 
Cholestatic diseases (%) 
Other (%) 
 
36  
28  
  9 
27  
 
43  
21  
11 
25  
 
40¥ 
24¥ 
9 
27  
 
29§ 
36§ 
8 
27  
 
<0.001 
<0.001 
  0.046 
  0.141 
MELD (median, IQR) 11 (7) 13 (7)* 11 (7)¥ 9 (5)§ <0.001 
Child-Pugh (%): 
A  (n: 712) 
B  (n: 575) 
C  (n: 299) 
 
45  
36  
19  
 
32* 
42 
25 
 
40¥ 
38¥  
23¥ 
 
58§ 
31§ 
12§ 
 
 
<0.001 
Previous 
decompensations (%): 
HE 
Ascites 
GI hemorrhage 
SBP 
HRS 
HCC 
 
 
18 
46 
20 
7 
3 
11 
 
 
32* 
57 
25 
10 
3 
11 
 
 
19¥ 
55¥ 
26¥ 
9¥ 
4¥ 
11 
 
 
8§ 
32§ 
11§ 
3§ 
1 
12 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
  0.057 
  0.512 
Endoscopy (n = 981) 
Esophageal varices (%) 
Large size varices (%) 
Gastric varices (%) 
Portal gastropathy (%) 
 
67 
40 
7 
56 
 
71 
38 
10 
59 
 
71¥ 
44 
7 
62¥ 
 
59§ 
37 
4§ 
48§ 
 
<0.001 
  0.824 
  0.046 
  0.003 
Analytical parameters 
(mean, SD): 
Bilirubin (mg/dL) 
Albumin (g/dL) 
INR 
Creatinine (mg/dL) 
Platelets (x10
3
/mm
3
) 
Hemoglobin (g/dL) 
 
 
2.40 (3.52) 
3.40 (0.72) 
1.40 (0.44) 
0.94 (0.58)  
116.5(67.8)  
12.1 (2.4) 
 
 
2.98 (4.17)*  
3.23 (0.68)*   
1.48 (0.43)* 
0.95 (0.70)  
93.6 (52.3)* 
11.7 (2.3) 
 
 
2.37 (3.35) 
3.34 (0.68)¥ 
1.41 (0.45)¥ 
0.96(0.58)  
115.9 (64.4)¥  
11.8 (2.4)¥ 
 
 
2.02 (3.08)§ 
3.56 (0.76)§ 
1.33 (0.43)§ 
0.92 (0.47) 
133.2 (75.0)§ 
12.6(2.3)§ 
 
 
<0.001 
<0.001 
<0.001 
  0.451 
<0.001 
<0.001 
Treatment (%): 
Lactulose or Lactitol 
Rifaximin or Neomycin 
Diuretics 
Beta-blockers 
 
24  
9  
52  
41  
 
35* 
17*  
64  
49 
 
28¥ 
10¥  
57¥ 
46¥ 
 
12§ 
 2§ 
40§  
31§ 
 
<0.001 
<0.001 
<0.001 
<0.001 
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L-SPSS: Large spontaneous portosystemic shunt; S-SPSS: Small-SPSS; W-SPSS: Without-SPSS; 
IQR: Interquartile range; SD: Standard deviation; HCV: Hepatitis C virus; MELD: Model for End-
stage Liver Disease; HE: Hepatic encephalopathy; GI: Gastrointestinal hemorrhage, SBP: 
Spontaneous bacterial peritonitis; HRS: Hepatorenal syndrome; HCC: Hepatocellular 
carcinoma; INR: International Normalized Ratio. 
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Table 2. Type of SPSS identified in L-SPSS and S-SPSS groups.  
Type of SPSS 
Frequency of 
L-SPSS  
(n = 488) 
Frequency of 
S-SPSS   
(n = 548) 
Splenorenal 46 18 
Paraumbilical 27 54 
Gastrorenal 9 15 
Mesocaval 5 8 
IMV -caval 4 0.5 
Mesorenal 3 0.5 
Others 4 3 
 
Results are shown as percentage.  
SPSS: Spontaneous portosystemic shunt; L-SPSS: Large-SPSS; S-SPSS: Small SPSS. IMV: Inferior 
mesenteric vein.  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
Table 3. Decompensating events during follow-up distributed by SPSS group. 
 Total 
(n=1729) 
L-SPSS 
(n = 488) 
S-SPSS 
(n =548) 
W-SPSS 
(n = 693) 
p 
HE  
Recurrent or persistent HE# 
HE West-Haven grade III-IV# 
33 
45 
45 
48* 
52 
45 
34¥ 
44 
44 
20§ 
37§ 
47 
<0.001 
  0.007 
  0.658 
GI bleeding  20 21 25¥ 15§   0.004 
Ascites  
Refractory ascites&  
58 
30 
63 
30 
70¥ 
33 
46§ 
27 
<0.001 
  0.397 
Spontaneous bacterial peritonitis 13 16 17¥ 9§ <0.001 
Other infections:  
- Spontaneous bacteremia 
- Pneumonia 
30 
4 
8 
31 
2 
8 
28 
5 
8 
30 
4 
7 
  0.730 
  0.139 
  0.877 
Hepatorenal syndrome  12 13 14¥ 9   0.041 
Hepatocellular carcinoma  20 18 22 19   0.552 
TIPS 6 7 9¥ 4§ 0.011 
 
Results are shown as percentages. # Percentages referred to the total number of patients with 
HE. & Percentages referred to the total number of patients with ascites. Significant differences 
among the three groups are reported as p value. Statistical differences (p≤0.05) between 
groups are indicated as * for comparison between L-SPSS versus S-SPSS, ¥ for S-SPSS versus W-
SPSS and § for L-SPSS versus W-SPSS. 
HE: Hepatic encephalopathy; GI: Gastrointestinal; SBP: Spontaneous bacterial peritonitis; HRS: 
Hepatorenal syndrome; HCC: hepatocellular carcinoma. L-SPSS: Large spontaneous 
portosystemic shunt; S-SPSS: Small-SPSS; W-SPSS: Without-SPSS; TIPS: Transjugular 
intrahepatic portosystemic shunt. 
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Table 4. Presence of episodes of hepatic encephalopathy (HE), with a recurrent or persistent 
course and grade III-IV from West-Haven criteria, and other decompensating events during 
follow-up, according to presence of SPSS and liver function subgroups (MELD score tertiles). 
 
Results are shown as percentages. Significant differences among the three groups are reported 
as p value. Statistical differences (p≤0.05) between groups are indicated as * for comparison 
between L-SPSS versus S-SPSS, ¥ for S-SPSS versus W-SPSS and § for L-SPSS versus W-SPSS. 
L-SPSS: Large spontaneous portosystemic shunt; S-SPSS: Small-SPSS; W-SPSS: Without-SPSS; 
HE: Hepatic encephalopathy; GI: Gastrointestinal. 
 
  
Episodes of HE  
L-SPSS 
(n = 488) 
S-SPSS 
(n =548) 
W-SPSS 
(n = 693) 
p 
MELD 6-9 23* 12¥ 5§ <0.001 
MELD 10-13 48* 33¥ 23§ <0.001 
MELD ≥14 59 57 48§ 0.043 
Recurrent or persistent HE  
L-SPSS with 
HE 
(n = 234 ) 
S-SPSS with 
HE 
(n = 186) 
W-SPSS with 
HE 
(n = 139) 
p 
MELD 6-9 54 29 47 0.790 
MELD 10-13 45 51 29 0.177 
MELD ≥14 55 42 36§ 0.013 
West-Haven scale: 
Grade III-IV  
L-SPSS with 
HE 
(n = 234) 
S-SPSS with 
HE 
(n = 186) 
W-SPSS with 
HE 
(n = 139 ) 
p 
MELD 6-9 35 29 47 0.482 
MELD 10-13 45 40 43 0.753 
MELD ≥14 46 51 51 0.438 
GI bleeding  
L-SPSS 
(n = 488) 
S-SPSS 
(n =548) 
W-SPSS 
(n = 693) 
p 
MELD 6-9 18 13 9§ 0.038 
MELD 10-13 22 30 20 0.444 
MELD ≥14 21 30 21 0.847 
Ascites  
L-SPSS 
(n = 488) 
S-SPSS 
(n =548) 
W-SPSS 
(n = 693) 
p 
MELD 6-9 40 41¥ 23§ <0.001 
MELD 10-13 53 70 56 0.751 
MELD ≥14 77 95 80 0.211 
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Supplementary Table 1. Inclusion per center and SPSS proportion.  
CENTER TOTAL L-SPSS  S-SPSS  W-SPSS  
Hospital Universitari Vall d´Hebron 
(Barcelona, Spain) 
299 
74 
25% 
103 
34% 
122 
41% 
Royal Free Hospital and UCL 
(London, United Kingdom) 
288 
65 
23% 
58 
20% 
165 
57% 
Hospital Universitario Ramón y Cajal 
(Madrid, Spain) 
185 
48 
26% 
29 
16% 
108 
58% 
Medical University of Vienna 
(Vienna, Austria) 
149 
57 
38% 
87 
58% 
5 
3% 
Hospital Clinic 
(Barcelona, Spain) 
141 
48 
34% 
30 
21% 
63 
45% 
University of Alberta 
(Edmonton, Canada) 
116 
41 
35% 
57 
49% 
18 
16% 
Hospital Universitario Puerta de 
Hierro (Madrid, Spain) 
95 
9 
9% 
8 
8% 
78 
82% 
University of Bonn 
(Bonn, Germany) 
94 
47 
50% 
46 
49% 
1 
1% 
Inselspital 
(Berne, Switzerland) 
79 
14 
18% 
47 
59% 
18 
23% 
Martin Luther University Halle-
Wittenberg, Halle (Halle, Germany) 
63 
13 
21% 
17 
27% 
33 
52% 
IRCCS San Donato  
(Milan, Italy) 
62 
18 
29% 
15 
24% 
29 
47% 
University Hospitals Leuven (Leuven, 
Belgium) 
61 
22 
36% 
27 
44% 
12 
20% 
Hospital General Universitario 
Gregorio Marañón 
(Madrid, Spain) 
49 
17 
34% 
16 
33% 
16 
33% 
Odense University Hospital, 
(Odense, Denmark) 
48 
15 
31% 
8 
17% 
25 
52% 
Total 1729 
488 
28% 
548 
32% 
693 
40% 
 
Results are shown as total number and percentage.  
 
L-SPSS: Large spontaneous portosystemic shunt; S-SPSS: Small-SPSS; W-SPSS: Without-SPSS. 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
 
Supplementary Table 2. Distribution of the different complications according to the type of L-
SPSS. 
 
Splenorenal 
(n = 226) 
Para-
umbilical 
(n = 130) 
Gastrorenal 
(n = 45) 
Mesocaval 
(n = 24) 
IMV-
caval 
(n = 19) 
Mesorenal 
(n = 16) 
p 
HE  50 52 40 63 44 30 0.226 
GI bleeding  22 21 21 21 35 13 0.234 
Ascites  61 71 53 71 63 56 0.134 
SBP  16 18 12 21 12 20 0.234 
HRS  17 11 9 8 12 7 0.286 
Esophageal varices 71 75 68 79 61 57 0.072 
Large varices  37 46 54 56 36 63 0.378 
Gastric varices  13 2 28 10 9 0 0.020 
Portal gastropathy 57 63 55 54 29 64 0.227 
 
Results are shown as percentages.  
L-SPSS: Large spontaneous portosystemic shunt; IMV: Inferior mesenteric vein. HE: Hepatic 
encephalopathy; GI: Gastrointestinal; SBP: Spontaneous bacterial peritonitis; HRS: Hepatorenal 
syndrome. 
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Supplementary Table 3. Univariate analysis for the identification of predictors at baseline (time 
0) of mortality or liver transplant at the end of follow-up.  
 
Regression 
coefficient 
p HR (95% CI) 
Age  0.006 0.069 1.01 (1.00-1.01) 
Gender  0.177 0.045 1.19 (1.00-1.42) 
Time of diagnosis of cirrhosis*  0.01 0.084 1.01 (0.99-1.02) 
Etiology: HCV  -0.009 0.915 0.99 (0.84-1.17) 
Etiology: Alcohol 0.077 0.349 1.08 (0.92-1.27) 
Hypertension -0.43 0.612 0.96 (0.81-1.13) 
Diabetes mellitus 0.19 0.027 1.20 (1.02-1.42) 
Platelets <150x10
9
/mm
3
 0.430 <0.001 1.54 (1.25-1.88) 
MELD score  0.115 <0.001 1.12 (1.11-1.14) 
Child-Pugh score 0.886 <0.001 1.36 (1.31-1.40) 
HCC  0.649 <0.001 1.91 (1.55-2.36) 
S-SPSS 0.307 0.001 1.36 (1.13-1.64) 
L-SPSS  0.471 <0.001 1.60 (1.33-1.93) 
SPSS (S + L) 0.387 <0.001 1.47 (1.26-1.73) 
 
SD: Standard deviation; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; SPSS: 
Spontaneous portosystemic shunt; L-SPSS: Large-SPSS; S-SPSS: Small-SPSS. *Indicates duration 
of cirrhosis after initial diagnosis. 
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Supplementary Table 4. Multivariate (Cox) analysis of factors related to death/liver transplant. 
 
Regression 
coefficient 
p HR (95% CI) 
Age 0.02 <0.001 1.02 (1.01-1.02) 
Gender 0.13 0.171 1.14 (0.95-1.36) 
Diabetes mellitus 0.12 0.163 1.13 (0.95-1.34) 
MELD score 0.13 <0.001 1.14 (1.12-1.15) 
HCC 0.82 <0.001 2.25 (1.80-2.81) 
Platelets <150x10
9
/mm
3
 0.23 0.036 1.26 (1.02-1.57) 
SPSS (S + L) 0.23 0.008 1.26 (1.06-1.49) 
 
L-SPSS was an independent factor related to death or liver transplant, with a HR 1.32 (1.08-
1.61; p=0.006). The HR for S-SPSS was 1.20 (95% CI 0.98-1.46; p=0.071). 
HR: Hazard ratio; CI: Confidence interval; MELD: Model for end-stage liver disease; HCC: 
Hepatocellular carcinoma; SPSS: Spontaneous portosystemic shunt; L-SPSS: Large-SPSS; S-SPSS: 
Small-SPSS. 
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Supplementary table 5. Presence of episodes of hepatic encephalopathy (HE), with a recurrent 
or persistent course and grade III-IV from West-Haven criteria  during follow-up, according to 
presence of SPSS and liver function subgroups (Child-Pugh class). 
 
Results are shown as percentages. Statistical differences (p≤0.05) between groups are 
indicated as * for comparison between L-SPSS versus S-SPSS, ¥ for S-SPSS versus W-SPSS and § 
for L-SPSS versus W-SPSS. 
HE: Hepatic encephalopathy; L-SPSS: Large spontaneous portosystemic shunt; S-SPSS: Small-
SPSS; W-SPSS: Without-SPSS. 
  
Episodes of HE 
L-SPSS 
(n = 488) 
S-SPSS 
(n =548) 
W-SPSS 
(n = 693) 
p 
Child A 28* 10 7§ <0.001 
Child B 50 41¥ 29§ <0.001 
Child C 78 68 61§  0.010 
Recurrent or persistent HE  
L-SPSS with 
HE 
(n = 234 ) 
S-SPSS with 
HE 
(n = 186) 
W-SPSS with 
HE 
(n = 139) 
P 
Child A 51 40 52 0.984 
Child B 50 47 33 0.074 
Child C 57 44 37§ 0.035 
West-Haven scale: 
Grade III-IV 
L-SPSS with 
HE 
(n = 234 ) 
S-SPSS with 
HE 
(n = 186) 
W-SPSS with 
HE 
(n = 139) 
P 
Child A 44 11 44 0.804 
Child B 38 47 45 0.398 
Child C 51 49 55 0.798 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
Supplementary table 6. Markers of portal hypertension (platelet count, spleen size, rate of 
varices and portal gastropathy on EGD endoscopy, TE, HVPG and percentage of CSPH) 
according to presence of SPSS in Child-Pugh A patients. 
Child-Pugh A 
(n = 712) 
L-SPSS 
(n = 144) 
S-SPSS 
(n = 196) 
W-SPSS 
(n = 372) 
p 
Platelets (x10
9
/mm
3
) 
mean (SD) 
95.7 (49.8) * 114.9 (58.6) ¥ 133.9 (65.7)§ <0.001 
Spleen diameter (cm) 
mean (SD) 
16* 14¥ 13§ <0.001 
EGD endoscopy (n = 371) 
L-SPSS 
(n = 81) 
S-SPSS 
(n = 108) 
W-SPSS 
(n = 182) 
 
Esophageal varices (%) 74 68¥ 47§ <0.001 
Gastric varices (%) 7 7 3 0.068 
Portal gastropathy (%) 46 58 41 0.180 
TE (n = 150) 
L-SPSS 
(n = 19) 
S-SPSS 
(n = 40) 
W-SPSS 
(n = 91) 
 
Liver stiffness (KPa) 
median (IQR) 
19 (24)* 27 (27)¥ 18 (17) 0.002 
HVPG measurement 
(n = 106) 
L-SPSS 
(n =23) 
S-SPSS 
(n = 31) 
W-SPSS 
(n = 52) 
 
HVPG (mmHg) 
mean (SD) 
15 (5)* 19 (7)¥ 11 (6)§ <0.001 
CSPH   
n (%) 
20 (87) 30 (97)¥ 27 (52)§ <0.001 
 
Results are shown as mean (SD), median (IQR) or percentages. Number of subjects available 
for every marker is indicated at the beginning of in every row. Statistical differences (p≤0.05) 
between groups are indicated as * for comparison between L-SPSS versus S-SPSS, ¥ for S-SPSS 
versus W-SPSS and § for L-SPSS versus W-SPSS. 
 
Three patients with L-SPSS had no CSPH: one patient had primary biliary cholangitis, one 
patient with mixed alcohol and hepatitis C etiology was abstinent and on beta-blockers, and 
finally one patient with hepatitis C was also on beta-blockers. One patient with S-SPSS and no 
CSPH was an abstinent alcoholic patient on beta-blockers.  
 
L-SPSS: Large-spontaneous portosystemic shunt; Small-SPSS: S-SPSS; W-SPSS: Without-SPSS; 
SD: Standard Deviation; EGD: Esophagogastroduodenal; TE: Transient elastography; IQR: 
Interquartile range; HVPG: Hepatic venous pressure gradient; CSPH: Clinically significant portal 
hypertension.  
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Supplementary table 7. Quality of life (modified Rankin Scale) according to presence of SPSS 
and MELD score subgroups. 
 L-SPSS 
(n = 488) 
S-SPSS 
(n =548) 
W-SPSS 
(n = 693) 
p 
MELD 6-9     
Autonomous 84* 92 95§  
Limitation 13 8 5 0.001 
Disability 3 0 0  
MELD 10-13     
Autonomous 82 82 88  
Limitation 17 17 11 0.071 
Disability 1 1 1  
MELD ≥14     
Autonomous 69 71 75  
Limitation 29 27 25 0.188 
Disability 2 2 0  
 
Results are shown as percentage. Statistical differences (p≤0.05) between pairs of value are 
indicated as * for comparison between L-SPSS and S-SPSS, ¥ for S-SPSS versus W-SPSS and § for 
L-SPSS versus W-SPSS.  
L-SPSS: Large spontaneous portosystemic shunt; S-SPSS: Small-SPSS; W-SPSS: Without-SPSS. 
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Supplementary table 8. Univariate (Cox) analysis of factors related to death or liver transplant 
in patients with preserved liver function (MELD score 6-9).  
 
Regression 
coefficient 
p HR (95% CI) 
Age 0.02 0.050 1.02 (1.00-1.03) 
Gender  -0.01 0.983 0.10 (0.67-1.48) 
Time of diagnosis of cirrhosis*  0.21 0.208 1.02 (0.99-1.06) 
Etiology: HCV  0.01 0.995 1.00 (0.68-1.47) 
Etiology: Alcohol 0.34 0.105 1.41 (0.93-2.13) 
Hypertension 0.21 0.283 1.23 (0.84-1.80) 
Diabetes mellitus 0.29 0.147 1.33 (0.90-1.97) 
Platelets <150x10
9
/mm
3
 0.10 0.619 1.12 (0.74-1.65) 
HCC  1.46 <0.001 4.31 (2.89-6.43) 
S-SPSS 0.49 0.024 1.64 (1.07-2.53) 
L-SPSS 0.37 0.185 1.45 (0.84-2.52) 
SPSS (S + L) 0.45 0.020 1.57 (1.08-2.30) 
 
CI: confidence interval; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HR: Hazard 
ratio; SPSS: Spontaneous portosystemic shunt; L-SPSS: Large-SPSS; S-SPSS: Small-SPSS. 
*Indicates duration of cirrhosis after initial diagnosis. 
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